FB-TW

Showing posts with label fraud. Show all posts
Showing posts with label fraud. Show all posts

Saturday, October 20, 2012

Don't accept everything called a scientific paper as truthful! - Groves

Fraud In Published Scientific Papers Rises Dramatically


Barry Groves Date: 02 Oct 2012

Fraud, suspected fraud, plagiarism and duplicate publications are the main reasons why scientific papers are retracted today, researchers from the Albert Einstein College of Medicine reported in PNAS (Proceedings of the National Academy of Sciences) today.

Misconduct occurs at ten times the rate it used to in 1975 among scientific papers - scientific papers refers to articles that are published in academic journals. Two thirds of all retractions today are due to misconduct.

Senior author Arturo Casadevall, M.D., Ph.D., the Leo and Julia Forchheimer Chair and professor of microbiology & immunology and professor of medicine at Einstein, and also editor-in-chief of mBio said:
"Biomedical research has become a winner-take-all game-one with perverse incentives that entice scientists to cut corners and, in some instances, falsify data or commit other acts of misconduct."
A survey carried out by the BMJ (British Medical Journal) in January 2012 revealed that 13% of doctors and scientists had seen colleagues deliberately fabricate or change data during their research to make sure that it was published.

The authors examined 2,047 articles that had been retracted from biomedical literature up to the end of May 2012. They had set out to find out why retractions occur. They consulted several secondary sources, including the NIH (National Institutes of Health, the Office of Research Integrity, as well as Retractionwatch.com.

The authors found that:
21% of retractions were due to mistakes (error)

67% of retractions were due to misconduct, which was broken down as:
- fraud or suspected fraud 43%
- duplicate publication 14%
- plagiarism 10%
- unknown or "miscellaneous" reasons 12%

The problem with very skillful fraud, Dr. Casadevall said, is that it is hard to discover. There are probably several fraudulent papers still published and not retracted because misconduct has not yet been detected.

The authors explained that previous studies that underestimated the extent of scientific misconduct had relied completely on notices of retraction issued by the journal, which are written by the authors of the papers themselves.

Dr. Casadevall said:
"Many of those notices are wrong. Authors commonly write, 'We regret we have to retract our paper because the work is not reproducible,' which is not exactly a lie. The work indeed was not reproducible - because it was fraudulent. Researchers try to protect their labs and their reputations, and these retractions are written in such a way that you often don't know what really happened."
The report showed that higher-impact factor journals seem to have especially high retraction rates. Dr. Casadevall said that today scientists are disproportionately rewarded for publishing lots of papers, which should ideally appear in prestigious journals - most likely this kind of pressure has contributed to the growing number of retractions.

Dr. Casadevall said:
"Particularly if you get your papers accepted in certain journals, you're much more likely to get recognition, grants, prizes and better jobs or promotions. Scientists are human, and some of them will succumb to this pressure, especially when there's so much competition for funding. Perhaps our most telling finding is what happened after 2005, which is when the number of retractions began to skyrocket. That's exactly when NIH funding began to get very tight."
Dr. Casadevall had put forward a number of solutions to address the problem of scientific misconduct in the journal Infection and Immunity, which included:
  • There should be more emphasis on the quality of publications rather than how many are published
  • When rating journals, there should not be so much emphasis on impact measures
  • The research community should aim for more cooperation and collaboration
  • More sustainable, stable and reliable resources for research funding should be developed
  • Career pathways should offer scientists more flexibility to make sure talented professionals are not loss due to poor funding
Retractions come from very few laboratories

The authors stressed that not all is gloom and doom. Dr. Casadevall explained that 38 laboratories accounted for 43% of all retractions last year. There are thousands and thousands of labs whose scientists publish articles in academic journals.

Dr. Casadevall said:
"So while we're not looking at a systemic disease, so to speak, in the scientific community, our findings do indicate a significant problem that needs to be addressed."
===============================================================
Read full article here.
 
Another view of the same phenomenon by Dr Mercola:
Misdeeds, Not Mistakes, Behind Most Scientific Retractions     
October 17 2012 
 
By Dr. Mercola
The medical and health fields are absolutely riddled with dogmatic beliefs that defy both commonsense and scientific truth. And yet they prevail because they are supposedly backed by "science."

But what if that science was not actually trustworthy, but rather a carefully orchestrated product... the result of massive conflict of interest, perpetuated by self-interested groups and industries that push unfavorable research findings under the proverbial rug, or even tweak their studies to have the "right" results?

Would it change the way you feel about your diet, your lifestyle and even your medical decisions if it turned out the research upon which your prior choices were made was actually not science at all, but fraud?

67 Percent of Research Retractions Made for "Misconduct," Including Fraud

Much like a potentially dangerous product can be recalled from the market, journals have the right to retract research papers if they turn out to be seriously flawed.

You might assume that most of those flaws would be due to simple human errors, but a review of over 2,000 biomedical and life-science research papers that have been retracted through May 2012 found that only 21 percent were retracted due to errors.1 Instead, the most common reason, in over 67 percent of cases, was misconduct, including fraud or suspected fraud (43.4%), duplicate publication (14.2%), and plagiarism (9.8%).

...And the more respected or influential the journal was, the more likely its retractions were to be attributed to fraud or suspected fraud! The study reveals a disturbing epidemic of deception going on in the research world, which has largely been downplayed, according to the researchers. In reality, scientific fraud has been on the rise for decades:
"Incomplete, uninformative or misleading retraction announcements have led to a previous underestimation of the role of fraud in the ongoing retraction epidemic. The percentage of scientific articles retracted because of fraud has increased ~10-fold since 1975." 2
While previous studies have looked into this issue, they typically used the study's retraction notice to determine the cause of the retraction. This is problematic in and of itself, however, because the study authors often write the announcements, and they're certainly not going to say they fabricated the data!

NPR pointed out the case of a 1993 study in Science,3 in which the data was found to have been falsified. But the retraction notice said only that "some experiments have not been reproducible."4 To get around these misleading announcements, the researchers for the current study independently verified the retraction reasons using information from the Federal Office of Research Integrity and independent media reports – and their results speak for themselves.

I wish I could say this is not a widespread issue... but a survey published in the BMJ earlier this year revealed that 13 percent of scientists or doctors had actually witnessed colleagues intentionally changing or fabricating research data in order to get a study published, while another 6 percent said they are aware of possible research misconduct at their institution that was never properly investigated...5

Drug Research May be Even Worse

The study above focused on retracted biomedical and life-science research papers, whereas a study earlier this year reviewed retracted studies in the drug and biomedical literature.6 The highest number of incidents of misconduct occurred in the drug literature, as compared to general biomedical literature. Nearly 75 percent of the retracted drug studies were attributed to scientific misconduct, which includes:
  • Data falsification or fabrication
  • Questionable veracity
  • Unethical author conduct
  • Plagiarism
The most unfortunate thing about this is that these are the types of studies many health care professionals rely on to make treatment recommendations. Large numbers of patients – potentially millions – can be affected when false findings are published, as the average lag time between publication of the study and the issuing of a retraction is 39 months. And that's if it's ever caught at all.

It's important to understand that our current medical system has been masterfully orchestrated by the drug companies to create a system that gives the perception of science when in reality it is a heavily manipulated process designed to deceive you into using expensive and potentially toxic drugs that benefit the drug companies more than it benefits your health. Across the board, drugmakers do an excellent job of publicizing the findings they want you to know, while keeping very quiet about the rest.

You see, all research is NOT published. And it should come as no surprise that drug studies funded by a pharmaceutical company that reaches a negative conclusion will rarely ever see the light of day... What this means is that even if you scour the medical literature to determine what the consensus is on any given medical topic, what you'll find is an overwhelming preponderance of data in favor of the drug approach that in no way, shape or form reflects the reality of the scientific investigation that went into that specific drug.

Ex-FDA Chief Says J&J Broke the Law Promoting Risperdal

Of course, it's not only in the research realm that drugs are fraudulently promoted; it occurs all the time in the marketing realm, too. Johnson & Johnson's (J&J) antipsychotic Risperdal was heavily promoted for unproven off-label uses for more than a decade, even after the U.S. Food and Drug Administration (FDA) issued warnings against the misleading claims. Doctors are well within their legal rights to prescribe a drug for off-label use; it's actually a common, albeit sometimes dangerous, practice. However, drug companies may not promote them for uses other than those that are FDA-approved.
Research has shown that up to two-thirds of prescriptions for Risperdal were for unapproved uses that had little or no scientific support.

How did this happen? Simple – J&J's Janssen unit sent out an army of salespeople to doctor's offices, nursing homes, Veteran's Administration facilities, and jails to tout Risperdal as a proverbial miracle drug for mental illness and dementia in the elderly, as well as for unapproved uses in children and adolescents. Former FDA Commissioner David Kessler, a pediatrician, said in an October trial report that the companies were in violation of the Federal Food, Drug, and Cosmetic Act when they promoted Risperdal for non-approved uses in children and adolescents. He noted:7
"The promotion of non-approved uses by a manufacturer, because it undercuts the system and safeguards of drug regulation, is concerning... The promotion of non-approved uses by a manufacturer of powerful drugs is more concerning... The promotion of non-approved uses in the most vulnerable children of powerful drugs is most concerning. Janssen's promotion of Risperdal, a powerful drug, for non-approved uses in the most vulnerable children is deeply troubling."

Drugs in Search of a Disease: Pharma Targets Women

And if they're not promoting a drug for unapproved uses, the drug companies are actively developing drugs based on entirely questionable – some might even say fictional – diseases. Women are often the targets for these drugs, as statistics show U.S. women use nearly 65 percent more drugs, on average, than men8– making them a more lucrative market for the drug companies. Drug and biotech companies are currently testing or awaiting FDA approval for more than 850 different drugs for diseases that "disproportionately affect American women."9

Writing in Scientific American, Judy Stone, MD, recently highlighted the almost comical pursuit to classify what were once ordinary feelings into unique woman-centered diseases:10
" ...women still are the primary targets for pharmaceutical advertising, in part because they can be captured for multiple products – if not quite from the cradle, at least from puberty, through pregnancy, to menopause and to grave. What are some of the consequences of this relentless focus on women's hormones and common symptoms? For one, it seems to promote a nation of hypochondriacs. It is extremely profitable for pharmaceutical companies, but it is not so good for the target of this attention, women... be wary of innocent sounding offers of drugs to relieve all of your discomforts."
Among some of the more curious diseases she included are:
  • Premenstrual Dysphoric Disorder (PMDD): "In my day, it was moodiness at 'that time of the month,' more typically known as bitchiness. We didn't have an ICD-9 or DSM code. We had uncomfortable days but knew that this, too, would pass. Now cyclical hormones are a disease," Stone writes. Now women are being treated with antidepressant drugs, which might increase the risk of suicide, to avoid these symptoms.
  • Hypoactive sexual desire disorder (HSDD): Otherwise known as lack of libido, various pills and "female Viagras" are clamoring to get to the market. Interestingly, lack of libido is often a side effect of antidepressant use.

The Solution is Within Your Hands...

The take-home message here is that even if a drug or treatment is "backed by science" or marketed as the miracle cure you've been waiting for, this in no way guarantees it is safe or effective. Likewise, if an alternative treatment has not been published in a medical journal, it does not mean it is unsafe or ineffective.

You've got to use all the resources available to you, including your own sense of common sense and reason, true experts' advice and other's experiences, to determine what medical treatment or advice will be best for you in any given situation. I advise you to remain skeptical but open – even if it is something I'm saying, you need to realize that YOU are responsible for your and your family's health, not me, and certainly not drug companies trying to sell their wares and convince you to take dangerous "symptom-cover-ups" disguised as science-based solutions.

If you're facing a health challenge it is best to identify a qualified natural health consultant – someone who really understands health at a foundational level and has had extensive experience in helping others resolve their health care challenges. Just make sure to see a competent regular physician to make certain any serious disorders like cancer are ruled out as well. In the meantime, do all you can to take control of your health so you stay healthy, and drug-free, in the first place.
============================================================
Read the complete article here.
A good video on "Why most published scientific research is probably false"
http://www.economist.com/blogs/graphicdetail/2013/10/daily-chart-2# 


 

Thursday, July 19, 2012

Harvard To Be Tried for Research Fraud

 

Harvard To Be Tried for Research Fraud

The US Court of Appeals, 1st Circuit has overturned a summary judgement by a lower court ordering a whistleblower lawsuit filed by Dr. Kenneth Jones against Harvard Medical School, its teaching hospitals, Brigham and Women’s and Massachusetts General Hospital, and Dr. Marilyn Albert (Principal Investigator) and Dr. Ronald Killiany to proceed to trial.
by VERA SHARAV
 
The case involves the largest Alzheimer’s disease [AD] research grants awarded by the National Institutes of Health (from 1980 through 2007) for a large project aimed at identifying early physical signs of Alzheimer’s by scanning certain regions of the brain with MRIs.

Dr. Jones was the chief statistician for the NIH grant. He blew the whistle after realizing that measurements used to demonstrate the reliability of the study had been secretly altered. Without these alterations, Dr. Jones explained, there was no statistical significance to the major findings of the study. When he insisted that the altered measurements be subjected to an independent reliability study, and that the manipulated results could not be presented as part of a $15 million federal grant extension application, he was terminated and his career came to an end.

The allegations in the suit concern multiple research fraud: data manipulation, significant deviations from the protocol, altered and re-traced MRI scans. To get positive results, Dr. Jones alleges, Dr. Killiany “fraudulently altered the MRI study data prior to 1998 to produce false results of a statistically significant correlation between conversion to AD and volume of the EC [entorhinal cortex].”

He further alleged that Dr. Albert and Dr. Killiany violated federal regulations (43 CFR 50.103(c)(3) by making false statements in the NIH grant application: Statements that “were predicated on falsified data that the defendants, knowing of this falsity, failed to take corrective action or disavow the data.”

In overturning the lower court and ordering the case to proceed to trial, the Court of Appeals cited the lower court failure to consider substantial evidence of research fraud, and failed to consider relevant testimony from three expert witnesses presented by Dr. Jones:
“A statistician who confirmed that the alterations were responsible for the statistical significance of the study results, a medical researcher who identified that the altered results could not be justified and were changed to establish a predetermined outcome, and a third expert who confirmed that NIH would not have funded the study had the falsity of the data been revealed during the application process and that Harvard failed to adequately investigate allegations of research fraud.”
The Court of Appeals decision states:
“the essential dispute is about whether Killiany falsified scientific data by intentionally exaggerating the re-measurements of the EC to cause proof of a particular scientific hypothesis to emerge from the data, and whether statements made in the Application about having used blinded, reliable methods to produce those results were true.”
Michael D. Kohn, one of the lead attorneys for Dr. Jones said:
“This is a major breakthrough holding universities accountable for the integrity of reported research results. Fraud committed in order to obtain NIH funding not only robs taxpayers, but also sets back long-term medical research goals. The facts of this case indicate that the report of false data misdirected research efforts at other institutions.”
This case also underscores an inconvenient truth about the financial stakes that drive clinical trials. Those who are persuaded to serve as human subjects “for the good of humanity” and “to help medical progress” believe in the integrity and high mindedness of medical researchers–especially those at premier academic institutions. That trust, however, is all too often misplaced. Vulnerable human subjects are being shamelessly exploited in invalid, most often commercially driven experiments.

Indeed, the rationale behind the Harvard brain scanning experiment was to justify early interventions.
Another example is Eli Lilly’s Alzeheimer’s imaging detection test (Amyvid) launched last month.
Inasmuch as no effective, safe treatment for Alzheimer’s exists, and ALL such screening tests have been demonstrably inaccurate and inconsistent, such an “early intervention” approach in clinical practice is unethical and controversial.

 
Tags: , , , , , , ,
=====================================================================
Read the complete article here.

NEJM editor: “No longer possible to believe much of clinical research published”

NEJM editor: “No longer possible to believe much of clinical research published”

Harvard Medical School’s Dr. Marcia Angell is the author of The Truth About the Drug Companies: How They Deceive Us and What to Do About It. But more to the point, she’s also the former Editor-in-Chief at the New England Journal of Medicine, arguably one of the most respected medical journals on earth. But after reading her article in the New York Review of Books called Drug Companies & Doctors: A Story of Corruption, one wonders if any medical journal on earth is worth anybody’s respect anymore.

“It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine.”

Dr. Angell cites the case of Dr. Joseph L. Biederman, professor of psychiatry at Harvard Medical School and chief of pediatric psychopharmacology at Harvard’s Massachusetts General Hospital. She explains:

“Thanks largely to him, children as young as two years old are now being diagnosed with bipolar disorder and treated with a cocktail of powerful drugs, many of which were not approved by the Food and Drug Administration (FDA) for that purpose, and none of which were approved for children below ten years of age.”

Biederman’s own studies of the drugs he advocates to treat childhood bipolar disorder were, as The New York Times summarized the opinions of its expert sources, “so small and loosely designed that they were largely inconclusive.”

In June 2009, an American senate investigation revealed that drug companies, including those that make drugs he advocates for childhood bipolar disorder, had paid Biederman $1.6 million in “consulting” and “speaking” fees between 2000 and 2007.

“Two of Biederman’s colleagues received similar amounts. After the revelation, the president of the Massachusetts General Hospital and the chairman of its physician organization sent a letter to the hospital’s physicians expressing not shock over the enormity of the conflicts of interest, but sympathy for the beneficiaries: “We know this is an incredibly painful time for these doctors and their families, and our hearts go out to them.”

Biederman’s failure to disclose his Big Pharma payments to his employers ar Harvard (as is required for all Harvard employees) has been under investigation* for the past two years by Harvard Medical School, in as journalist Alison Bass describes this: “what must be the longest investigation in that school’s history”).

Dr. Angell’s article contains bombshell after bombshell, all gleaned during her tenure as NEJM editor. For example, on the subject of doctors who are bought and paid for by Big Pharma, she writes:

“No one knows the total amount provided by drug companies to physicians, but I estimate from the annual reports of the top 9 U.S.-based drug companies that it comes to tens of billions of dollars a year in North America alone.By such means, the pharmaceutical industry has gained enormous control over how doctors evaluate and use its own products. Its extensive ties to physicians, particularly senior faculty at prestigious medical schools, affect the results of research, the way medicine is practiced, and even the definition of what constitutes a disease.”

Revelations like this from medical profession insiders cast serious doubt on more than what’s printed on the pages of these medical journals.

Your physician reads these journals, treatment decisions are changed, care is affected, drugs are prescribed – all based on Big Pharma-funded medical ghostwriter-prepared journal articles from physicians who fraudulently claim to be the study authors. Then you walk out of your doctor’s office with a prescription for a drug that may or may not kill you, based on treatment protocols written by doctors like Biederman who are on the take from Big Pharma.

A very recent example of the sad reality over at the once-prestigious New England Journal of Medicine is their decision to publish a drug company-funded review article. This review attempts to discredit emerging research suggesting that many years of using Merck’s Fosamax or Procter & Gamble’s Actonel (both osteoporosis drugs in a class called bisphosphonates) could actually result in more leg bone fractures.

Not surprisingly, drug manufacturers of bisphosphonates are fighting back ferociously against this emerging (independent) research. A Merck-funded review paper published in the NEJM on March 24, 2010 concludes:

“The occurrence of fracture of the subtrochantericor diaphyseal femur was very rare, even among women who had been treated with bisphosphonates for as long as 10 years.”

Sounds promising for Big Pharma. But if you look very, very closely, the article’s fine print confesses:
“The study was underpowered for definitive conclusions.”
You might justifiably ask yourself why a medical journal would stoop to publishing a meaningless scientific paper that the paper’s own authors admit lacks any conclusion. Even more troubling than a journal article that was itself bought and paid for by Merck, is the conflict of interest disclosure list at the bottom of this NEJM article. It reads like a Who’s Who of Big Pharma.

Of the 12 study authors listed in the NEJM article, at least three are full-time employees of Merck or Novartis. Each one of the other nine admit owning equity interests in or receiving cash, travel expenses, or “consulting and lecture fees” from companies including Merck, Novartis, Amgen, Roche Nycomed, Procter & Gamble, AstraZeneca, GlaxoSmithKline, Medtronics, Nastech, Nestle, Fonterra Brands, OnoPharma, Osteologix, Pfizer, Eli Lilly, Sanofi-Aventis, Tethys, Unilever,Unipath, Inverness Medical, Ortho Clinical Diagnostics, OSIProsidion, or Takeda.
Why is the New England Journal of Medicine or any other credible medical journal accepting for publication articles submitted by paid employees of pharmaceutical companies?

As a cardiac patient, I’m gobsmacked by what appears to be this systemic corruption of not only medical journals who continue to publish what they clearly know is tainted research linked to drug marketing, but of the very doctors whom patients trust to look out for us. Since my heart attack in 2008, I take a fistful of cardiac meds every day, and I have no clue which of them were prescribed for me based on flawed research or tainted medical journal articles funded by the very companies that make my drugs.

And worse, neither do my doctors.

Happily, there are other decent physicians out there who, like Dr. Angell, are just as outraged as she is. Her targets are not just guilty of unethical conflict of interest – they are criminals who should be charged with endangering our health while padding their wallets.

Read Dr. Angell’s article from the New York Review of Books, called Drug Companies & Doctors: A Story of Corruption.

* NEWS UPDATE: “Massachusetts General Hospital Discloses Sanctions against Three Psychiatrists for Violating Ethics Guidelines”, July 1, 2011: The Boston Business Journal said today that three psychiatrists have been sanctioned for failing to adequately report seven-figure payments they received from drug companies.

Drs. Joseph Biederman, Thomas Spencer and Timothy Wilens disclosed the disciplinary actions against them in a note to colleagues. According to a copy of the note made public upon request by the hospital, the three doctors:

• must refrain from “all industry-sponsored outside activities” for one year

• for two years after the ban ends, must obtain permission from Mass. General and Harvard Medical School before engaging in any industry-sponsored, paid outside activities and then must report back afterward

• must undergo certain training

• face delays before being considered for “promotion or advancement.”

The three doctors have been under the political microscope since June 2008 when Senator Charles Grassley, R-Iowa, began investigating conflicts of interest involving clinicians. Biederman and Wilens have since admitted to accepting $1.6 million from drug companies whose drugs they were promoting; Spencer took $1 million.

Senator Grassley said, according to an online version of the Congressional record:

“These three Harvard doctors are some of the top psychiatrists in the country, and their research is some of the most important in the field. They have also taken millions of dollars from the drug companies.”
See also:
==========================================================
Read the complete article here.